Yushin Company (6482) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
21 Jul, 2026Executive summary
Net sales rose 21.6% year-over-year to ¥12,133 million in the first half, driven by strong custom-ordered equipment sales and increased demand in Japan and Europe.
Operating profit increased 31.4% year-over-year to ¥911 million, supported by higher sales despite increased personnel expenses.
Ordinary profit declined 12.2% year-over-year to ¥738 million due to foreign exchange losses.
Profit attributable to owners of parent decreased 1.0% year-over-year to ¥534 million.
The company will change its trade name to "Yushin Company" effective April 2025.
Financial highlights
Gross profit improved to ¥4,895 million from ¥4,113 million year-over-year; gross profit margin for the first half: 40.3%.
Operating profit margin: 7.5% (first half FY2025); full-year forecast: 10.2%.
Comprehensive income dropped to ¥329 million from ¥1,373 million year-over-year, mainly due to negative foreign currency translation adjustments.
Total assets decreased to ¥41,565 million from ¥42,821 million at the previous fiscal year-end, mainly due to a reduction in cash and deposits.
Orders received increased 15.6% year-over-year to ¥12,990 million; backlog decreased to ¥9,617 million.
Outlook and guidance
Full-year consolidated forecasts unchanged: net sales of ¥25,500 million (+8.0% YoY), operating profit of ¥2,600 million (+6.7% YoY), and profit attributable to owners of parent of ¥1,800 million (+6.4% YoY).
Annual dividend forecast maintained at ¥20 per share; dividend payout ratio target of 30% or more.
Anticipates continued sales growth in Japan and Asia in the second half, especially in the mobility and medical fields.
Expects higher raw material and labor costs but projects profit growth due to increased sales.
Latest events from Yushin Company
- Sales surged 19.7% year-over-year, but profit margins narrowed on higher costs.6482
Q1 202521 Jul 2026 - Net sales and profit grew in FY2025, but FY2026 guidance signals declines amid global uncertainty.6482
Q4 202521 Jul 2026 - Net sales rose 14.5% year-over-year, with robust growth in Japan and Europe.6482
Q3 202521 Jul 2026 - Operating profit rose despite lower sales, with Asia growth offset by Europe weakness.6482
Q1 202621 Jul 2026 - Profits fell sharply on weak medical equipment sales, but dividends and buybacks are maintained.6482
Q2 202621 Jul 2026 - Profits and sales fell sharply in FY2026, but a strong rebound is forecast for FY2027.6482
Q4 202621 Jul 2026 - Profits and sales fell sharply year-over-year, with Europe showing the largest decline.6482
Q3 202621 Jul 2026